Omnicell, Inc. (OMCL) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

54/ 100

GoAI Score

Hold

Valuation

51

Fair Value

Sentiment

73

Bullish

Risk

41

Elevated Risk

Momentum

57

Neutral

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Industry: Medical - Healthcare Information Services
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $35.82

$35.17$36.055

52-week range

Current $35.82

$29.06$55.00

Open: $35.25
Previous close: $34.83
Volume: 303.07K
Market cap: 1.63B USD
50-day average: $34.6788; +3.29% above average
200-day average: $39.882; -10.18% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 2.09B USD
P/E (TTM): 41.9×
P/B (TTM): 1.26×
P/S (TTM): 1.31×
EV / EBITDA: 20.52×
Earnings yield: 0.10%
Free cash flow yield: 4.17%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 44.77%
Operating margin: 4.73%
Net margin: 3.13%
Return on equity: 0.17%
Return on assets: 0.10%
Return on invested capital: 0.14%

Financial health

Debt / equity: 0.15×
Current ratio: 1.43×
Altman Z-score: 2.58
Piotroski F-score: 8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

1.18B USD+6.53%

Operating income

11.67M USD+3361.42%

Net income

2.05M USD-83.62%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.18B USD	1.11B USD	1.15B USD	1.3B USD	1.13B USD
Cost of goods sold	676.8M USD	641.24M USD	647.18M USD	706.96M USD	577.37M USD
Gross profit	508.04M USD	471M USD	499.93M USD	588.99M USD	554.65M USD
Research and development	87.74M USD	90.41M USD	93.29M USD	104.97M USD	75.72M USD
Selling, general, and administrative	408.64M USD	380.25M USD	425.97M USD	486.34M USD	389.43M USD
Operating expenses	496.38M USD	470.67M USD	519.26M USD	591.31M USD	465.15M USD
Interest income	11.9M USD	24.9M USD	14.76M USD	—	—
Interest expense	3.91M USD	4.53M USD	—	130K USD	22.39M USD
Depreciation and amortization	86.63M USD	89.76M USD	95.56M USD	99.17M USD	84.93M USD
Operating income	11.67M USD	337K USD	−19.33M USD	−2.32M USD	89.51M USD
Net income	2.05M USD	12.53M USD	−20.37M USD	5.65M USD	77.85M USD

Company facts updated Oct 11, 2026.

Earnings

Latest fiscal-year EPS: 0.044; FY2025 · -83.59% year over year
Latest fiscal-year revenue: 1.18B USD; FY2025 · +6.53% year over year
Next fiscal-year EPS consensus: 2.27; FY2026 · 5 analysts
Next fiscal-year revenue consensus: 1.24B USD; FY2026 · 6 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$56.67

58.21% upside

Past 12 months12-month forecastHigh $65.00Average $56.67Low $50.00

OMCL news

defenseworld.netOct 11, 2026

Financial Contrast: Baxter International (NYSE:BAX) and Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ: OMCL - Get Free Report) and Baxter International (NYSE: BAX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of…

Read source

businesswire.comOct 8, 2026

Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026.

Read source

zacks.comOct 2, 2026

Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read source

zacks.comSep 16, 2026

Here's Why Omnicell (OMCL) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read source

prnewswire.comSep 3, 2026

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.

Read source